Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Tech medical breakthrough

New endometriosis diagnostic tests emerge

Analysis based on 17 articles · First reported Sep 05, 2026 · Last updated Sep 05, 2026

Sentiment
40
Attention
2
Articles
17
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The emergence of new endometriosis diagnostic tests could expand the market for non-invasive diagnostics, benefiting developers like EndoSure and Ziwig. Regulatory approvals and adoption by health systems like the NHS may drive revenue growth, though U.S. market entry faces regulatory hurdles.

Medical diagnostics Biotechnology Healthcare

Endometriosis UK, a chronic inflammatory disease affecting 1 in 10 women worldwide, often goes undiagnosed for a decade or more due to symptom normalization and lack of provider expertise. New diagnostic tests, EndoSure and Endotest, are now available in some countries outside the U.S. EndoSure, developed by Maryland-based EndoSure, measures electrical signals in the gut via abdominal sensor pads. Endotest, developed by French company Ziwig, analyzes saliva for microRNAs. The United Kingdom's United Kingdom — National Health Service has published draft guidance recommending both tests for three years to speed diagnosis in primary care. EndoSure is submitting an FDA application in the U.S., while Ziwig is pursuing availability through certified laboratories without FDA approval. U.S. doctors view these tests as helpful adjuncts, not replacements, for existing diagnostic methods. Patient Zoë Armstrong, diagnosed after years of symptoms, underwent excision surgery and advocates with the Endometriosis Foundation.

ngo
The condition is the focus of the new diagnostic tests; improved diagnosis could expand treatment markets.
Importance 100.0 Sentiment 0.0
priv
French company developing Endotest; expanding into U.S. market.
Importance 80.0 Sentiment 70.0
govactor
Adopting new tests for three years; could improve diagnosis rates and patient outcomes.
Importance 70.0 Sentiment 30.0
govactor
Regulatory body; approval decisions will determine U.S. market access.
Importance 60.0 Sentiment 0.0
cnt
NHS adoption may set precedent for other health systems.
Importance 50.0 Sentiment 30.0
cnt
Potential market for new tests; regulatory pathway being pursued.
Importance 50.0 Sentiment 30.0
per
Patient whose story illustrates diagnostic delays; advocates for awareness.
Importance 30.0 Sentiment 0.0
per
Founder of EndoSure; leading FDA submission.
Importance 30.0 Sentiment 0.0
per
Ziwig's representative; overseeing U.S. availability efforts.
Importance 30.0 Sentiment 0.0
ngo
Cited for statistics on diagnostic delays; not directly impacted.
Importance 20.0 Sentiment 0.0
priv
Hospital where Dr. Billow practices; provides clinical perspective.
Importance 20.0 Sentiment 0.0
ngo
Patient advocacy group; education efforts may raise awareness.
Importance 20.0 Sentiment 0.0
per
Physician at Mount Sinai West; provides expert commentary.
Importance 20.0 Sentiment 0.0
per
Physician at Cleveland Clinic; provides expert commentary.
Importance 20.0 Sentiment 0.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.